Eli Lilly
2,345 hedge funds and large institutions have $225B invested in Eli Lilly in 2022 Q1 according to their latest regulatory filings, with 168 funds opening new positions, 885 increasing their positions, 866 reducing their positions, and 105 closing their positions.
60% more first-time investments, than exits
New positions opened: 168 | Existing positions closed: 105
29% more funds holding in top 10
Funds holding in top 10: 79 → 102 (+23)
2% more funds holding
Funds holding: 2,303 → 2,345 (+42)
4% more capital invested
Capital invested by funds: $217B → $225B (+$7.89B)
2% more repeat investments, than reductions
Existing positions increased: 885 | Existing positions reduced: 866
0.3% more ownership
Funds ownership: 82.58% → 82.88% (+0.3%)
12% less call options, than puts
Call options by funds: $1.36B | Put options by funds: $1.55B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$834M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$531M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$404M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$314M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$302M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.1B |
| 2 |
Barclays
London,
United Kingdom
|
-$408M |
| 3 |
Lilly Endowment
Indiananapolis,
Indiana
|
-$337M |
| 4 |
Jennison Associates
New York
|
-$323M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$254M |
LLY Hedge Fund Activity: Q1 2022 in Review
2,345 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Eli Lilly (LLY) for Q1 2022, worth a combined $225B — up 3.6% from $217B a quarter earlier.
Buyers outnumbered sellers: 168 funds opened new LLY positions and 105 closed out — a net gain of 63 holders — while 885 added to existing stakes and 866 trimmed.
The largest buyer was Capital World Investors, adding an estimated $834M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.1B.
- 2,345 institutional investors held Eli Lilly (LLY) as of Q1 2022, up from 2,303 in Q4 2021.
- Funds reported $225B of Eli Lilly stock for Q1 2022, up 3.6% quarter-over-quarter.
- 168 funds opened new Eli Lilly positions in Q1 2022 and 105 closed out, a net change of +63 holders.
- The largest Eli Lilly buyer in Q1 2022 was Capital World Investors, an estimated $834M added.
- The largest Eli Lilly seller in Q1 2022 was T. Rowe Price Associates, an estimated $1.1B sold.
Based on aggregated 13F filings for Q1 2022.